AI in Drug Development is cutting trial setup and regulatory paperwork, with Novartis and GSK citing major time and cost savings.
AI in Drug Development helps Pharma Cut Trial Admin Time
Original Article by Maggie Fick and Michael Erman | Reuters | 26 January 2026
AI in Drug Development is cutting trial setup and regulatory paperwork, with Novartis and GSK citing major time and cost savings.
More Posts
NHLS Scrambles as Pathology Services Funding Runs Dry
The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt
Read more...
Momentum Group Posts Record Earnings
Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.
Read more...
Sanlam Writes Down AfroCentric to Nil but Won’t Sell
Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.
Read more...